Results 11 to 20 of about 53,199 (230)

Bortezomib alters sour taste sensitivity in mice

Toxicology Reports, 2017
Chemotherapy-induced taste disorder is one of the critical issues in cancer therapy. Bortezomib, a proteasome inhibitor, is a key agent in multiple myeloma therapy, but it induces a taste disorder.
Akihiro Ohishi, Kentaro Nishida, Karin Miyamoto, Mizuka Imai, Ryoko Nakanishi, Kyoko Kobayashi, Akiko Hayashi, Kazuki Nagasawa   +7 more
doaj   +2 more sources

Bortezomib-induced polyneuropathy

, 2013
Background: Peripheral neuropathy is a frequent side effect of bortezomib chemotherapy. Relatively little is known about the clinical characteristics of this neuropathy, especially with respect to pain.
Boer, Marjan, Rampen, Anneke, Sonneveld, Pieter, van den Bent, Martin; id_orcid, Heuvel, I, Jongen, Joost   +5 more
core   +10 more sources

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations [PDF]

Biomolecules, 2021
Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells. BTZ plays an irreplaceable role in the treatment of mantle cell lymphoma and multiple myeloma.
Jianhao Liu, Ruogang Zhao, Xiaowen Jiang, Zhaohuan Li, Bo Zhang   +4 more
openaire   +3 more sources

Carrier-Free Berberine/Nitidine Chloride Self-Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma. [PDF]

Adv Sci (Weinh)
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Lv Y, Liu S, Wu H, Li G, Rong Y, Li G, Zhu Y, Zhong Q, Ou R, Shen H, Liu Z, Huang J, Wang Z, Lin P, Zhang Q, Yu G, Yin Z.   +16 more
europepmc   +2 more sources

Breathless on bortezomib [PDF]

BMJ Case Reports, 2011
The authors describe a case of episodic acute pneumonitis occurring after repeated doses of bortezomib, a drug being used increasingly to treat multiple myeloma. The delay in presentation each time with fever, dyspnoea, hypoxia and interstitial radiological changes contributed to under-recognition of this complication, which has so far been described ...
Devaki, O'Riordan, John, Houghton, Roger, Chisholm, B Ronan, O'Driscoll   +3 more
openaire   +2 more sources

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma

, 2022
The development of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is well recognised in multiple myeloma (MM).
Christopher Thompson (7899002), N O'Connor-Byrne (14138973), Siobhan Glavey (7896182), Philip Murphy (10045793), John Quinn (7898771), R Tudor (14138981)   +5 more
core   +2 more sources

BORTEZOMIB INDUCED SUBCONJUNCTIVAL HEMORRHAGE [PDF]

, 2017
Many drugs are used in the treatment of multiple myeloma but Thalidomide, Lenalidomide, Bortezomib, dexamethasone and their combination remains the main stay of treatment. The molecular formula of bortezomib is C19H25BN4O4 and its chemical IUPAC name is [
Karthik S Udupa, Balaji Ommurugan, Navin Patil, Karthik Rao   +3 more
core   +3 more sources

Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial

, 2022
We conducted a phase II trial to prospectively evaluate the efficacy and safety of bortezomib-cyclophosphamide-dexamethasone (VCD) induction, autologous stem cell transplantation (ASCT), VCD consolidation, and bortezomib maintenance in transplant ...
Takayuki Ishikawa (12081674), Kayoko Nagata (510494), Akihito Yonezawa (12081683), Yoshihiro Kuwabara (286904), Akifumi Takaori-Kondo (510501), Takeshi Maeda (304955), Toshiyuki Kitano (12081668), Hiromi Kitao (12081698), Masayuki Kobayashi (142755), Shinjiro Tominari (586335), Kouhei Yamashita (510498), Mitsumasa Watanabe (12081680), Junya Kanda (454650), Shinji Yasuno (524104), Masaaki Tsuji (12081671), Kenji Ueshima (524105), Kazunori Imada (428120), Kohsuke Asagoe (12081692), Masaharu Nohgawa (12081677), Toshinori Moriguchi (9638591), Hirokazu Hirata (12081686), Yasunori Ueda (1816504), Mitsuru Itoh (2185678), Nobuyoshi Arima (12081689), Naoyuki Anzai (12081695), Hitoshi Ohno (5023949), Hiroyuki Muranushi (12081665), Takeo Nakayama (388728), Ihhwa Kim (12081701), Kiyomi Kawagishi (12081704)   +29 more
core   +1 more source

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

Journal of Hematology & Oncology, 2018
Background Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib.
Zhihong Zheng, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu, Yubin Kang   +7 more
doaj   +1 more source

642 Repurposing bortezomib for improved treatment of melanoma by exploiting immunogenic cell death

, 2022
Immunogenic cell death (ICD) constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies.
Daignault-Mill, SM, S.M. Daignault-Mill, N.K. Haass, Gabrielli, B, R.J. Ju, B. Gabrielli, Zeng, B, Haass, NK, D. Moi, Spoerri, L, L. Spoerri, Moi, D, R. Dolcetti, Ju, RJ, Dolcetti, R, B. Zeng   +15 more
core   +1 more source